ALGS:NSD-Aligos Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 25.54

Change

-0.42 (-1.62)%

Market Cap

USD 1.04B

Volume

0.04M

Average Target Price

USD 34.00 (+33.12%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a synthetic oligonucleotide that is in Phase I clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company is also developing ALG-020572, an antisense oligonucleotide to decrease HBsAg levels; and ALG-055009, a small molecule THR-ß agonist for the treatment of non-alcoholic steatohepatitis. In addition, it is developing siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. The company has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting SARS-CoV-2; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-10.75 (-6.19%)

USD69.53B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.98 (-0.46%)

USD55.62B 20.48 15.19
REGN Regeneron Pharmaceuticals, Inc

-2.76 (-0.57%)

USD51.68B 15.90 12.28
BNTX BioNTech SE

-6.11 (-3.45%)

USD50.45B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

+1.42 (+0.84%)

USD37.30B 54.77 36.21
BGNE BeiGene, Ltd

-4.85 (-1.56%)

USD29.11B N/A N/A
RPRX Royalty Pharma plc

-0.65 (-1.53%)

USD25.78B 22.60 15.82
SGEN Seagen Inc

-1.11 (-0.82%)

USD24.72B 38.00 35.77
GMAB Genmab A/S

+1.09 (+3.06%)

USD24.27B 26.59 3.52
CVAC CureVac N.V

-7.93 (-7.27%)

USD22.38B N/A N/A

ETFs Containing ALGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.63% 47% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.63% 46% F 22% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 1.04B 71% C- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 4.70 51% F 37% F
Price / Cash Flow Ratio -14.04 67% D+ 80% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -64.37% 47% F 18% F
Return on Invested Capital -126.32% 11% F 5% F
Return on Assets -29.72% 42% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 27.86 0% N/A 0% N/A
Short Percent 4.59% 65% D 42% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector